JP7767289B2 - Ｒｓｐｏ１タンパク質およびその使用 - Google Patents

Ｒｓｐｏ１タンパク質およびその使用

Info

Publication number
JP7767289B2
JP7767289B2 JP2022541989A JP2022541989A JP7767289B2 JP 7767289 B2 JP7767289 B2 JP 7767289B2 JP 2022541989 A JP2022541989 A JP 2022541989A JP 2022541989 A JP2022541989 A JP 2022541989A JP 7767289 B2 JP7767289 B2 JP 7767289B2
Authority
JP
Japan
Prior art keywords
protein
rspo1
cells
pharmaceutical composition
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022541989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509189A (ja
JP2023509189A5 (https=
Inventor
コロンバ，パトリック
シルヴァノ，セレナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Nice Sophia Antipolis UNSA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2023509189A publication Critical patent/JP2023509189A/ja
Publication of JP2023509189A5 publication Critical patent/JP2023509189A5/ja
Priority to JP2025182517A priority Critical patent/JP2026021430A/ja
Application granted granted Critical
Publication of JP7767289B2 publication Critical patent/JP7767289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022541989A 2020-01-10 2021-01-08 Ｒｓｐｏ１タンパク質およびその使用 Active JP7767289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182517A JP2026021430A (ja) 2020-01-10 2025-10-29 Ｒｓｐｏ１タンパク質およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305016 2020-01-10
EP20305016.6 2020-01-10
PCT/EP2021/050289 WO2021140209A1 (en) 2020-01-10 2021-01-08 Rspo1 proteins and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182517A Division JP2026021430A (ja) 2020-01-10 2025-10-29 Ｒｓｐｏ１タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2023509189A JP2023509189A (ja) 2023-03-07
JP2023509189A5 JP2023509189A5 (https=) 2023-12-07
JP7767289B2 true JP7767289B2 (ja) 2025-11-11

Family

ID=69185555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022541989A Active JP7767289B2 (ja) 2020-01-10 2021-01-08 Ｒｓｐｏ１タンパク質およびその使用
JP2025182517A Pending JP2026021430A (ja) 2020-01-10 2025-10-29 Ｒｓｐｏ１タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182517A Pending JP2026021430A (ja) 2020-01-10 2025-10-29 Ｒｓｐｏ１タンパク質およびその使用

Country Status (10)

Country Link
US (1) US20230241161A1 (https=)
EP (1) EP4087863A1 (https=)
JP (2) JP7767289B2 (https=)
KR (1) KR20220152202A (https=)
CN (1) CN114929731A (https=)
AU (1) AU2021205639A1 (https=)
BR (1) BR112022013468A2 (https=)
CA (1) CA3163861A1 (https=)
IL (1) IL294571A (https=)
WO (1) WO2021140209A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120813594A (zh) * 2023-01-19 2025-10-17 迪奥根克斯公司 R-spondin蛋白的重组变体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506871A (ja) 2006-10-20 2010-03-04 デウトスクフエス クレブスフオルスチュングスゼントルム ストイフトウング デス オフフエントリクヘン レクフトス 血管新生及び脈管形成のモジュレーターとしてのｒスポンジン
JP2021020900A (ja) 2019-07-29 2021-02-18 国立大学法人北海道大学 糖代謝異常改善剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO2008088524A2 (en) * 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
WO2016193497A1 (en) * 2015-06-04 2016-12-08 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
IL310154A (en) * 2021-07-15 2024-03-01 Diogenx Recombinant variants of r-spondin proteins and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506871A (ja) 2006-10-20 2010-03-04 デウトスクフエス クレブスフオルスチュングスゼントルム ストイフトウング デス オフフエントリクヘン レクフトス 血管新生及び脈管形成のモジュレーターとしてのｒスポンジン
JP2021020900A (ja) 2019-07-29 2021-02-18 国立大学法人北海道大学 糖代謝異常改善剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J Neurophysiol ，2019年，Vol.121，pp.928-939
JOURNAL OF BIOLOGICAL CHEMISTRY，2010年07月09日，VOL:285, NR:28，PAGE(S):21292 - 21302
VICTOR SHING CHI WONG，ROLE OF R-SPONDIN-1 IN THE REGULATION OF PANCREATIC [BETA]-CELL BEHAVIOUR，A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy，University of Toronto，2011年，PAGE(S):１-133，https://tspace.library.utoronto.ca/bitstream/1807/29914/6/Wong_Victor_S_201106_PhD_thesis.pdf

Also Published As

Publication number Publication date
KR20220152202A (ko) 2022-11-15
IL294571A (en) 2022-09-01
EP4087863A1 (en) 2022-11-16
AU2021205639A1 (en) 2022-07-14
US20230241161A1 (en) 2023-08-03
CA3163861A1 (en) 2021-07-15
WO2021140209A1 (en) 2021-07-15
JP2026021430A (ja) 2026-02-10
JP2023509189A (ja) 2023-03-07
CN114929731A (zh) 2022-08-19
BR112022013468A2 (pt) 2022-09-13

Similar Documents

Publication Publication Date Title
JP6810190B2 (ja) Ｆｇｆ２１突然変異体及びその使用
JP5823954B2 (ja) Ｆｇｆ２１変異体及びその使用
US20230031280A1 (en) Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
JP2022046520A (ja) ＩＬ－２２ポリペプチド及びＩＬ－２２Ｆｃ融合タンパク質並びに使用方法
JP2020524661A (ja) 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ−１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
JP2026021430A (ja) Ｒｓｐｏ１タンパク質およびその使用
US20230340044A1 (en) Recombinant variants of r-spondin proteins and their use
JP2026506476A (ja) Ｒ－スポンジンタンパク質の組換えバリアントおよびその使用
CN117980323A (zh) R-spondin蛋白的重组变体及其用途
KR20210082189A (ko) Glp-2 융합 폴리펩티드 및 위장 병태를 치료 및 예방하기 위한 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7767289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150